[{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"fcdaa581-7698-4699-bff1-a8e70321bccc","acronym":"DESTINY-CRC02","url":"https://clinicaltrials.gov/study/NCT04744831","created_at":"2021-02-09T13:53:02.487Z","updated_at":"2025-02-25T14:59:42.256Z","phase":"Phase 2","brief_title":"Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04744831 - DESTINY-CRC02","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • HER-2 • BRAF • TMB • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type","tags":["EGFR • HER-2 • BRAF • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki)"],"overall_status":"Completed","enrollment":" Enrollment 122","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 10/08/2024","study_completion_date":" 10/08/2024","last_update_posted":"2024-11-19"}]